Compare VATE & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VATE | VRCA |
|---|---|---|
| Founded | 1994 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.5M | 88.0M |
| IPO Year | 1996 | 2018 |
| Metric | VATE | VRCA |
|---|---|---|
| Price | $7.68 | $4.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 93.8K | 83.3K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,246,000,000.00 | $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $94.44 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 12.55 | ★ 370.22 |
| 52 Week Low | $3.75 | $3.28 |
| 52 Week High | $21.30 | $9.82 |
| Indicator | VATE | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 52.97 | 42.61 |
| Support Level | $6.48 | $4.65 |
| Resistance Level | $8.20 | $5.94 |
| Average True Range (ATR) | 0.48 | 0.28 |
| MACD | 0.20 | -0.03 |
| Stochastic Oscillator | 88.28 | 21.95 |
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments. Its segments include Infrastructure, Life Sciences and Spectrum, and Other segment. Through its subsidiaries it provides fully integrated structural and steel construction services; supports healthcare and biotechnology product development; and operates Over-The-Air (OTA) broadcasting stations across the United States (U.S.) including Puerto Rico.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.